Nine-month results of the REFORM study: a prospective, single-arm, multicenter clinical study of the safety and effectiveness of the Formula™ balloon-expandable stent for treatment of renal artery stenosis
- PMID: 22581488
- DOI: 10.1002/ccd.24481
Nine-month results of the REFORM study: a prospective, single-arm, multicenter clinical study of the safety and effectiveness of the Formula™ balloon-expandable stent for treatment of renal artery stenosis
Abstract
Objectives: To evaluate the 9-month safety and effectiveness outcomes of the Formula™ balloon-expandable renal stent (Cook Medical, Bloomington, IN) for the treatment of atherosclerotic renal artery stenosis (RAS) following suboptimal angioplasty.
Background: Atherosclerotic RAS can cause hypertension and ischemic nephropathy. When clinically indicated, an interventional approach with renal angioplasty and stent implantation is the preferred method for revascularization of atherosclerotic renal artery stenoses.
Methods: The REFORM study is a prospective, multicenter, single-arm study of stent implantation following suboptimal PTRA using the Formula stent. One hundred patients with atherosclerotic ostial renal artery lesions =18 mm in length with a >50% residual stenosis following PTA were enrolled. The primary endpoint was 9-month primary patency.
Results: The 9-month primary patency rate was 91.7%. The 9-month major adverse event rate was 2.2%. Mean systolic blood pressure was significantly decreased at follow-up (from 150 ± 21 mm Hg at baseline to 141 ± 21 mm Hg at 9 months; P = 0.003). Mean serum creatinine (SCr) level and mean estimated glomerular filtration rate (eGFR) were not significantly different at 9 months. A clinically meaningful improvement in renal function (i.e., =25% increase in eGFR or =0.5 mg/dl decrease in SCr) was observed in 9% of patients at 1 month and 12% of patients at 9 months. A clinically meaningful decline in renal function (i.e., =25% decrease in eGFR or =0.5 mg/dl increase in SCr) was observed in only 3% of patients at 1 month and 7% of patients at 9 months.
Conclusions: The Formula stent was safe and effective in treating atherosclerotic RAS following suboptimal angioplasty.
Trial registration: ClinicalTrials.gov NCT00631540.
Keywords: hypertension; ischemic nephropathy; renal artery disease; renal failure; renal stent; revascularization.
© 2013 Wiley Periodicals, Inc.
Comment in
-
A new renal stent in the denervation era.Catheter Cardiovasc Interv. 2013 Aug 1;82(2):274. doi: 10.1002/ccd.25071. Catheter Cardiovasc Interv. 2013. PMID: 23878035 No abstract available.
Similar articles
-
Significant reduction in systolic blood pressure following renal artery stenting in patients with uncontrolled hypertension: results from the HERCULES trial.Catheter Cardiovasc Interv. 2012 Sep 1;80(3):343-50. doi: 10.1002/ccd.24449. Epub 2012 Jun 27. Catheter Cardiovasc Interv. 2012. PMID: 22511402 Clinical Trial.
-
Evaluation of the safety and effectiveness of renal artery stenting after unsuccessful balloon angioplasty: the ASPIRE-2 study.J Am Coll Cardiol. 2005 Sep 6;46(5):776-83. doi: 10.1016/j.jacc.2004.11.073. J Am Coll Cardiol. 2005. PMID: 16139124
-
Ten-year experience with renal artery in-stent stenosis.J Vasc Surg. 2011 Apr;53(4):1026-31. doi: 10.1016/j.jvs.2010.10.092. Epub 2011 Jan 7. J Vasc Surg. 2011. PMID: 21215576
-
Restenosis after stenting of atherosclerotic renal artery stenosis: is there a rationale for the use of drug-eluting stents?Catheter Cardiovasc Interv. 2006 Jul;68(1):125-30. doi: 10.1002/ccd.20773. Catheter Cardiovasc Interv. 2006. PMID: 16755597 Review.
-
Stenting for atherosclerotic renal artery stenosis.Tech Vasc Interv Radiol. 2010 Jun;13(2):134-45. doi: 10.1053/j.tvir.2010.02.008. Tech Vasc Interv Radiol. 2010. PMID: 20540922 Review.
Cited by
-
Cardiovascular Disease Prevention in Patients With Atherosclerotic Renovascular Disease-Induced Resistant Hypertension: Further Considerations for 24-Hour Blood Pressure Profiles.J Am Heart Assoc. 2022 Sep 6;11(17):e025901. doi: 10.1161/JAHA.122.025901. Epub 2022 Aug 17. J Am Heart Assoc. 2022. PMID: 35975740 Free PMC article. No abstract available.
-
Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design.Clin Res Cardiol. 2020 Mar;109(3):289-302. doi: 10.1007/s00392-020-01595-z. Epub 2020 Feb 7. Clin Res Cardiol. 2020. PMID: 32034481 Free PMC article.
-
Update on intervention versus medical therapy for atherosclerotic renal artery stenosis.J Vasc Surg. 2015 Jun;61(6):1613-23. doi: 10.1016/j.jvs.2014.09.072. J Vasc Surg. 2015. PMID: 26004332 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous